Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto. She is the Co-Director of the Hematology/Oncology Clinical Research Group there. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and an Associate Scientist at the Li Ka Shing Knowledge Institute. 

She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and has been the Co-Chair of the Annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is currently the President of the Canadian Cardio-Oncology Network. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Dr. Susan Dent is a Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology at Duke University.  She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the Canadian Cancer Trials Group. 

Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity. She is the Founder and past-president of the Cardiac Oncology Network, an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity.

Dr. Fradley is an Associate Professor of Medicine at the University of South Florida with a joint appointment at Moffitt Cancer Cente. He is the director of the combined Moffitt Cancer Center-University of South Florida Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine.  

He remained at Johns Hopkins for internal medicine residency and then went on to complete fellowships in both cardiology and clinical cardiac electrophysiology at Massachusetts General Hospital. His research focuses on all aspects of cardio-oncology, however as a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He has co-authored numerous articles in the field of cardio-oncology. He is also actively involved in undergraduate and graduate medical education mentoring medical students, residents and fellows. He developed and serves as the program director for cardio-oncology fellowship at the University of South Florida and Moffitt Cancer Center. He is the co-director of the biomedical research tract in the Scholarly Concentrations Program at the University of South Florida, Morsani College of Medicine. He is also the medical director for the Harvey Simulation Elective and teaches the cardiovascular pathophysiology course for the second year medical students.

Dr. Harrison is the chief of medicine at HCA Memorial Hospital in Tampa Florida and a professor of medicine at the University of South Florida Morsani College of Medicine. Dr. Harrison’s medical career can be divided into 5 multiyear parts.

(1) Education and training culminating in being the first USF cardiac fellow to complete training with the privilege of being named the director of the cath lab at the Tampa VA Hospital while still a fellow but independently funded by the Florida Heart Association. As a fellow, Dr. Harrison received the key to the city of Tampa by the mayor for being a Founder of the Tampa Fire Rescue Program. (2) Hospital based Academic Career at Tampa General Hospital where he was the Associate Director and then Co-director of the Cardiology Center and a Founder of the University of South Florida Medical School and Hillsborough County EMS service (3) Private Practice Group and Joint Venture This period of his professional life was the creation of a 11 man multihospital physician’s group and founding an outpatient diagnostic heart center as a Co-General partner with a Hospital and with physician limited partners. (4) Corporate Medical Director experience as a national medical director of cardiology , education and research for a 19 acute care hospital network. Creation of a free standing Advanced Cardiac Imaging Center and training program for cardiac PET/CT, CCTA, and cardiac MRI in Tampa, Fl. (5) Sherlock Plaque Analysis Program / AI Curating a CCTA 5,000 case data base and creation of the Sherlock Program for predicting cardiac prognosis based on plaque morphology, composition, and function to predict cardiac events. Startup company PrivaCors to develop this concept nationally with artificial intelligence. PrivaCors has been chosen by IBM Watson Healthcare to join their 24company collaborative to implement AI in medical imaging. Co-founded Cardio-Oncology and founded Cardio-Orthopaedics , a new subspecialty of cardiology to contain the cardiac risk of orthopedic TJA surgery.

Dr. Roohi Ismail-Khan is an Associate Member at Moffitt Cancer Center in the Comprehensive Breast Program. She completed her Internal Medicine Residency at the University of South Florida and served as Chief Resident. She completed her Medical Oncology Fellowship at the H. Lee Moffitt Cancer Center as well as completed her MS in Clinical Research during her fellowship. 

Her research interests include reducing or eliminating long-term effects of chemotherapy and to improve quality of life in breast cancer patients, particularly in metastatic breast cancer patients. Her clinical research is also focused upon identifying high risk patient cohorts and minimizing cardiovascular side effects in patients receiving cardiotoxic therapy. She serves as principal investigator on both investigator initiated and pharmaceutical sponsored clinical trials. She serves as the co-director of the USF/Moffitt Cardio-Oncology program. Dr. Ismail-Khan is also an active teacher and mentor for USF medical students, Internal Medical residents, and Medical Oncology Fellows.

Dr. Lenihan, has been active in cardio-oncology and heart failure, for nearly 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer.

His current projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis.  He is the PI of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for multiple myeloma and recently completed the PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity and has been intimately involved in the latest treatment trials for cardiac amyloidosis.  He recently moved to Washington University in St Louis to enhance and expand their Cardio-Oncology Center of Excellence.  Dr Lenihan continues to enhance and foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome, and the development of novel therapeutics including gene therapy for chronic heart failure.

Dr. Lyon is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. He is the current president of the British Cardio-Oncology Society (formerly the UK Cardio-Oncology Consortium) and the cardiology advisor to the charity Macmillan Cancer. Dr. Lyon was recently appointed chair of the European Society of Cardiology Heart Failure Association Cardio-Oncology Study Group and he is a co-author of their ESC Position Statement on Cardio-Oncology. He is a member of the International Cardio-Oncology Society and is co-chair of the 2017 ICOS-BCOS hosted Global Cardio-Oncology Summit in London.

Dr. Patel is an Assistant Professor of Medicine at the University of South Florida (USF) with clinical appointments at Moffitt Cancer Center, James A. Haley Veterans’ Affairs Hospital and Tampa General Hospital. As a practicing cardiologist, her clinical expertise is in Advanced Cardiac Imaging, including echocardiography, cardiac magnetic resonance imaging and cardiac computed tomography. 

She earned her Bachelor of Science degree at University of Miami (UM) and her Medical Doctorate at Florida State University College of Medicine. After completing residency at UM she completed both general and imaging fellowships at USF, later joining as faculty. She has special interest in multimodality imaging in diagnosis of cardiovascular disease and medical education. Her research interests include cardiomyopathy in Friedreich’s Ataxia and valvular disease. She has authored papers in cardio-oncology pertaining to multimodality imaging and medical education. She currently serves as the Director of the Advanced Cardiac Imaging Fellowship Program at USF and is a member of the American College of Cardiology Academic Council.

Javier Pinilla-Ibarz, MD, PhD, is a Senior Member, Head of the Lymphoma Section and Director of Immunotherapy in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida, Tampa, Florida. 

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006; and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. In this regard, Dr. Pinilla-Ibarz has participated in multiple clinical trials involving tyrosine kinase inhibitors, some of them now approved. As Director of Immunotherapy for Malignant Hematology, he has been involved in developing new immunotherapeutic approaches in malignant hematology. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. His laboratory is interested in epigenetic immunoregulation in lymphoid and myeloid leukemias. Other research focuses are on the role of the bone marrow microenvironment in mediating resistance to TKIs and the interaction of TKIs with the immune system. Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association and the American Society of Clinical Oncology and other national/international meetings. His work has been published in journals including Blood, Nature Immunology, Seminars of Hematology and Leukemia. He has also authored multiple book chapters. Dr. Pinilla-Ibarz received both his MD and PhD from the University of Zaragoza, School of Medicine, Spain. He completed his residency in medicine and a fellowship in Hematology at La Paz University Hospital in Madrid, Spain; and after he moved to the US, he also completed a residency in Internal Medicine at Cornell Medical Center and a fellowship in Hematology/Oncology at the Memorial Sloan Kettering Cancer Center in New York City.

Dr. Kenneth Shain is an Assistant Member at the H. Lee Moffitt Cancer Center and Research Institute (Moffitt), with a primary appointment in the Department of Malignant Hematology, and a secondary appointment in the Department of Tumor Biology. He also serves as the Scientific Director of the Moffitt Myeloma Working Group (MMWG) and as the Director of the ORIEN MM Disease Interest Group (DIG) at Moffitt. 

As a clinician-scientist he investigates the pathobiology of multiple myeloma (MM) and mechanisms of therapy resistance, including intrinsic mechanisms of resistance and that mediated by bone marrow tumor microenvironment (TME), to identify novel targets and tools to improve the management of multiple myeloma (MM). On the clinical side he treats MM patients and directs MM clinical trials. Dr. Shain's research has three major focuses: (i) development and use of pharmacoproteomic tools to identify vulnerabilities of MM and to identify drivers of therapy resistance in the context of the TME; (ii) development and use of ex vivo tools informed by mathematical models for personalized management of MM; and (iii) development and use of tissue, molecular and clinical bio-repositories/databases centered around gene expression profiling, whole exome sequencing (WES) and RNA sequencing (RNAseq) of MM patient specimens, to identify predictive and prognostic molecular biomarkers. The ultimate objective of Dr. Shain's research program is to address the critical need to identify tractable vulnerabilities to inform the development of targeted therapeutics with biomarkers facilitating truly personalized management in MM.